SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

CORONA Remedies - Quaterly Results

03 Feb 2026 Evaluate
The revenue for the December 2025 quarter is pegged at Rs. 3424.20 millions, about 15.03% up against Rs. 2976.90 millions recorded during the year-ago period.The Company's Net profit for the December 2025 quarter have declined marginally to Rs. 412.50  millions as against Rs. 447.70 millions reported during the corresponding quarter ended.Operating Profit saw a handsome growth to 854.00 millions from 701.80 millions in the quarter ended December 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202512 202412 % Var
Sales 3424.20 2976.90 15.03 3424.20 2976.90 15.03 3424.20 2976.90 15.03
Other Income 22.40 7.60 194.74 22.40 7.60 194.74 22.40 7.60 194.74
PBIDT 854.00 701.80 21.69 854.00 701.80 21.69 854.00 701.80 21.69
Interest 16.60 23.90 -30.54 16.60 23.90 -30.54 16.60 23.90 -30.54
PBDT 646.40 677.90 -4.65 646.40 677.90 -4.65 646.40 677.90 -4.65
Depreciation 94.50 96.90 -2.48 94.50 96.90 -2.48 94.50 96.90 -2.48
PBT 551.90 581.00 -5.01 551.90 581.00 -5.01 551.90 581.00 -5.01
TAX 139.40 133.30 4.58 139.40 133.30 4.58 139.40 133.30 4.58
Deferred Tax -31.60 -7.60 315.79 -31.60 -7.60 315.79 -31.60 -7.60 315.79
PAT 412.50 447.70 -7.86 412.50 447.70 -7.86 412.50 447.70 -7.86
Equity 611.60 611.60 0.00 611.60 611.60 0.00 611.60 611.60 0.00
PBIDTM(%) 24.94 23.57 5.79 24.94 23.57 5.79 24.94 23.57 5.79

CORONA Remedies Share Price

1559.80 -5.15 (-0.33%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×